Posted by Michael Wonder on 08 Aug 2018
NICE publishes final appraisal determination for Alecensa
8 August 2018 - The determination relates to the use of alectinib hydrochloride for the first-line treatment of patients with untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
Alectinib hydrochloride is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer in adults.
It is recommended only if the company provides alectinib hydrochloride according to the commercial arrangement.
